| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
H-Phe-β-Ala-OH does not have a specific biological target as a drug. It is a metabolite formed from protein breakdown. The compound may be recognized by certain peptidases and amino acid transporters, but it is not designed to interact with specific receptors or enzymes for therapeutic purposes. Its primary value is as a research tool for studying protein metabolism and amino acid catabolism.
|
|---|---|
| ln Vitro |
In vitro, H-Phe-β-Ala-OH is used as a substrate in enzymatic assays to study the activity of peptidases. It may also be used in studies of amino acid transport and metabolism. The compound does not exhibit significant pharmacological activities such as receptor binding or enzyme inhibition. Its role in research is as a reagent for studying protein digestion, peptide metabolism, and the role of dipeptides in biological systems.
|
| ln Vivo |
H-Phe-β-Ala-OH is not a pharmacologically active compound and therefore does not have defined in vivo activity as a therapeutic agent. It is a metabolite and an incomplete breakdown product of protein digestion or catabolism. When administered to animals, it would likely be metabolized by peptidases to release phenylalanine and alanine. Its primary value is as a research tool for studying protein metabolism and amino acid catabolism.
|
| Enzyme Assay |
In vitro enzyme assays for H-Phe-β-Ala-OH are typically designed to study peptidase or protease activity. A standard protocol involves incubating the compound with an enzyme preparation in a suitable buffer. The hydrolysis of the dipeptide bond releases phenylalanine and alanine, which can be quantified by HPLC or mass spectrometry. The progress of the reaction can be monitored, and kinetic parameters can be determined. These assays are used to characterize the substrate specificity of peptidases.
|
| Cell Assay |
In vitro cellular assays using H-Phe-β-Ala-OH are limited because the compound is primarily a metabolite. However, it can be used in cell culture studies to investigate peptide transport and metabolism. Cells are cultured in media supplemented with the compound, and its uptake and hydrolysis are monitored. The effects of increased phenylalanine and alanine availability on cellular metabolism can be assessed.
|
| Animal Protocol |
In vivo animal studies with H-Phe-β-Ala-OH are not typically conducted for therapeutic purposes. However, it may be used in metabolic studies to investigate protein digestion and amino acid catabolism. A typical protocol involves administration of the compound to rodents, followed by blood and tissue sampling to measure its levels and metabolites. These studies help to understand the metabolism of dipeptides and their role in protein turnover.
|
| ADME/Pharmacokinetics |
As a small, hydrophilic dipeptide, H-Phe-β-Ala-OH is expected to be rapidly metabolized in the body. Its pharmacokinetic properties are characteristic of small peptides, with rapid clearance and short half-life. Detailed pharmacokinetic data are not typically reported, as the compound is primarily a metabolite rather than a drug candidate.
|
| Toxicity/Toxicokinetics |
H-Phe-β-Ala-OH is generally considered to have low toxicity, consistent with its status as an endogenous metabolite. It is a dipeptide composed of the amino acids phenylalanine and alanine. Standard laboratory safety precautions, including the use of personal protective equipment, are recommended. No significant systemic toxicity is anticipated at typical research doses.
|
| References | |
| Additional Infomation |
Phenylalanine-alanine (Phe-Ala) is a dipeptide formed from L-phenylalanine and L-alanine residues, and is a metabolite. Functionally, it is related to both L-phenylalanine and L-alanine, and is a zwitterionic tautomer of Phe-Ala. Phe-Ala has been reported to be detected in Trypanosoma brevicornu, and relevant data are available for reference.
H-Phe-β-Ala-OH (Phenylalanylalanine, CAS 3918-87-4) is a dipeptide formed from L-phenylalanine and L-alanine residues. Its molecular formula is C₁₂H₁₆N₂O₃ and its molecular weight is 236.27 g/mol. It is an incomplete breakdown product of protein digestion or protein catabolism. It has a role as a metabolite. It is intended for research use only. |
| Molecular Formula |
C12H16N2O3
|
|---|---|
| Molecular Weight |
236.26704
|
| Exact Mass |
236.116
|
| CAS # |
3918-87-4
|
| PubChem CID |
5488196
|
| Appearance |
White to off-white solid powder
|
| Density |
1.222g/cm3
|
| Boiling Point |
506ºC at 760mmHg
|
| Melting Point |
241℃ (Decomposition)
|
| Flash Point |
259.8ºC
|
| Index of Refraction |
1.565
|
| LogP |
1.236
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
17
|
| Complexity |
275
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N
|
| InChi Key |
MIDZLCFIAINOQN-WPRPVWTQSA-N
|
| InChi Code |
InChI=1S/C12H16N2O3/c1-8(12(16)17)14-11(15)10(13)7-9-5-3-2-4-6-9/h2-6,8,10H,7,13H2,1H3,(H,14,15)(H,16,17)/t8-,10-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~423.24 mM)
DMSO : ~4.35 mg/mL (~18.41 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2324 mL | 21.1622 mL | 42.3245 mL | |
| 5 mM | 0.8465 mL | 4.2324 mL | 8.4649 mL | |
| 10 mM | 0.4232 mL | 2.1162 mL | 4.2324 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
